US2023210808A1PendingUtilityA1

4-(phenoxyalkyl)thio)-phenoxyacetic acids and analogs

Assignee: JANSSEN PHARMACEUTICA NVPriority: Sep 19, 2003Filed: Mar 13, 2023Published: Jul 6, 2023
Est. expirySep 19, 2023(expired)· nominal 20-yr term from priority
A61K 31/192A61K 31/277C07C 323/62C07C 59/70C07C 59/68C07D 333/28C07C 323/20C07C 317/22C07D 333/16C07C 323/60C07C 323/19A61P 3/00A61P 3/04A61P 3/06A61P 43/00A61P 7/00A61P 9/00A61P 9/10A61P 9/12A61P 3/10A61K 31/10C07C 59/58
86
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as PPAR delta modulators to treat or inhibit the progression of, for example, dyslipidemia.

Claims

exact text as granted — not AI-modified
1 - 56 . (canceled) 
     
     
         57 . A compound of Formula (II): 
       
         
           
           
               
               
           
         
         wherein
 X is a covalent bond; 
 Y is S or O; 
 - - - - - W - - - - - represents a group selected from —CH═, —CH 2 —, —CH 2 —CH 2 —, —CH 2 —CH═, and —CH═CH—; 
 Z is selected from O, CH, and CH 2 , provided when Y is O, Z is O; 
 R 1  and R 2  are independently selected from H, C 1-3  alkyl, C 1-3  alkoxy, halo, and NR a R b  wherein R a  and R b  are independently H or C 1-3  alkyl; 
 R 3  is independently selected from H, F, Cl, methyl, and methoxy and 
 R 4  is selected from H, Cl, and methyl; provided that R 3  and R 4  are not both H; 
 n is 1 or 2; 
 
         or a pharmaceutically acceptable salt thereof. 
       
     
     
         58 . (canceled) 
     
     
         59 . (canceled) 
     
     
         60 . (canceled) 
     
     
         61 . The compound of  claim 57  wherein Y is O. 
     
     
         62 . The compound of  claim 57  wherein Y is S. 
     
     
         63 . The compound of  claim 57  wherein Z is O. 
     
     
         64 . The compound of  claim 57  wherein Z is CH or CH 2 . 
     
     
         65 . The compound of  claim 57  wherein - - - - - W - - - - - represents —CH 2 — or —CH 2 —CH 2 —. 
     
     
         66 . The compound of  claim 65  wherein - - - - - W - - - - - represents —CH 2 —. 
     
     
         67 . The compound of  claim 57  wherein - - - - - W - - - - - represents —CH═, —CH 2 —CH═, or —CH═CH—. 
     
     
         68 . (canceled) 
     
     
         69 . The compound of  claim 57  wherein R 1  and R 2  are independently selected from H, C 1-3  alkyl, C 1-3  alkoxy, F, Cl, and Br. 
     
     
         70 . The compound of  claim 69  wherein R 1  and R 2  are independently selected from H, methyl, methoxy, F and Cl. 
     
     
         71 - 75 . (canceled) 
     
     
         76 . The compound of  claim 57  wherein R 1  is selected from H, CF 3 , methyl, Cl, and methoxy, and R 2  is selected from H, Cl, and methyl. 
     
     
         77 - 93 . (canceled) 
     
     
         94 . A pharmaceutical composition comprising a compound of  claim 57 . 
     
     
         95 . (canceled)

Join the waitlist — get patent alerts

Track US2023210808A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.